EZZ is in a solid financial position to build on its growth strategy after a strong Q3 FY22 which has seen the company close the quarter with ~$10.4 million in cash. Genomic-tech firm, EZZ Life Science Holdings (ASX:EZZ) has closed…
Shared from the 3/31/2022 Financial Review eEdition Life sciences is one of the fastest growing industries in the world, with companies investing heavily in scientific research for the betterment of humankind. The industry comprises companies operating across a broad spectrum;…
By George Tchetvertakov March 4, 2022 There is a palatable global trend towards greater health consciousness and it’s accelerating, Australian life science company EZZ Life Science (ASX: EZZ) told attendees at its gastrointestinal health conference last week. With the COVID-19…
EZZ has achieved a significant milestone after being reclassified on the ASX as the genome-specialist looks to broaden its market share in the biotech and life sciences sector. Aussie-listed genomic-tech firm, EZZ Life Science Holdings (ASX:EZZ) has had its listing…
Speakers including Luis Vitetta, Clinical Prof. with @Sydney_Uni, Gemma Acton, Network Finance Manager @7NewsSydney and Glenn Cross, EZZ Life Science Chairman.